Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical indicators suggest the stock is in oversold territory, with a concerning 56% decline over the past six months. This latest price point underscores a significant downturn for the genetic testing and precision medicine company, which has seen its stock value decrease by 43.18% over the past year. Despite the challenges, the company maintains a healthy current ratio of 1.9 and achieved revenue growth of 12.15% in the last twelve months. Investors are closely monitoring Myriad Genetics’ performance, as the company navigates through industry headwinds and strives to implement strategies that could potentially reverse the negative trend and restore shareholder confidence. InvestingPro subscribers can access 7 additional key insights and a comprehensive Pro Research Report for deeper analysis of MYGN’s potential turnaround prospects.
In other recent news, Myriad Genetics has experienced a series of significant developments. The company saw a 12.2% revenue growth in the past year, which UBS attributes to improvements in Myriad Genetics’ growth profile. However, UBS assigned a Neutral rating to the stock, citing concerns regarding GeneSight reimbursement as a potential near-term issue. Leerink Partners also downgraded the company’s stock to Market Perform, reducing its 2025 growth estimate to 2.5% due to potential challenges such as Medicaid cuts and competitive pressures.
Scotiabank (TSX:BNS) revised its price target for Myriad Genetics, acknowledging these potential challenges, yet the company remains committed to achieving approximately 12% revenue compound annual growth rate through 2026. It is planning to launch the Precise MRD test for breast cancer in the first half of 2026 and has made significant investments in lab technologies.
In legal matters, Myriad Genetics settled a series of shareholder derivative lawsuits, agreeing to implement specified corporate governance reforms and pay up to $950,000 in attorneys’ fees and expenses. These recent developments reflect the company’s ongoing commitment to growth and profitability amidst various policy and legal challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.